Walmart Adds Free GLP-1 Drugs, Insulin to Employee Benefits
Walmart is expanding health coverage to include Ozempic, Mounjaro, inhalers, and insulin at no cost for eligible employees with Type 2 diabetes.
Walmart is broadening its employee health benefits to cover select GLP-1 medications, insulin, and inhalers at no cost, marking a significant expansion of pharmacy coverage for the retail giant's large workforce.
Under the updated plan, employees diagnosed with Type 2 diabetes will be able to access Novo Nordisk's Ozempic and Eli Lilly's Mounjaro without out-of-pocket expense, provided they meet prior authorization requirements set by the company's benefit administrators.
Read more Starbucks Weighs Chipotle Takeover Bid, Sources Say →
The move reflects a broader shift among major U.S. employers grappling with how to manage the surging demand for GLP-1 drugs, which have gained widespread attention for both diabetes treatment and weight management. By requiring prior authorization, Walmart aims to balance expanded access with cost controls to limit benefit expenditures.
Adding inhalers and insulin to the zero-cost coverage list signals that Walmart is taking a more comprehensive approach to chronic disease management across its employee base, potentially improving health outcomes while reducing long-term medical claims for the self-insured retailer.
As one of the largest private employers in the United States, Walmart's benefits decisions carry outsized influence and could prompt other large employers to revisit their own GLP-1 and chronic disease coverage policies. Continue reading at Business News.
